Last reviewed · How we verify

NCT07530965

OMEGA-3-FATTY ACIDS IN CHILDREN WITH SICKLE CELL DISEASE

Not yet recruiting NA Last updated 15 April 2026
What this trial tests

NA trial testing Flaxseed in Sickle Cell Disease (SCD) in 20 participants. Not yet recruiting.

Timeline
1 June 2026
Primary endpoint
31 December 2027
31 December 2028

Quick facts

Lead sponsorUniversity of Alabama at Birmingham
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date1 June 2026
Primary completion31 December 2027
Estimated completion31 December 2028

Drugs / interventions tested

Conditions studied

Sponsor

University of Alabama at Birmingham

Who can join

Adults 5 to 18, any sex, with Sickle Cell Disease (SCD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this feasibility study is to investigate the role of a dietary supplement in modulating the gut microbiota and improving pain outcomes in children with sickle cell disease (SCD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Flaxseed

Trials testing the same drug.

Other recruiting trials for Sickle Cell Disease (SCD)

Currently open trials in the same condition.

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07530965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing